Results 101 to 110 of about 10,064 (258)

β‐1,4‐galactosyltransferase 1 inhibitors modulate cellular N‐glycan profiles

Biotechnology Progress, EarlyView.
Graphical representation of the study workflow used to investigate the effects of known in vitro galactosyltransferase inhibitors on cell culture performance and recombinant IgG galactosylation. Abstract N‐glycosylation is a key post‐translational modification of proteins influencing their physicochemical properties as well as biological activity. This
Jaka Kranjc, Stane Pajk, Marko Anderluh, Anja Pišlar, Matjaž Brinc   +4 more
wiley   +1 more source

Living Microbial Drugs

Chemistry – A European Journal, EarlyView.
The introduction outlines the review scope. Microbial cell factories as living drugs cover host–gut microbiota, bacteria, yeast, and other microbial systems, with comparative host advantages. Engineering strategies include synthetic circuits, quorum sensing, and memory.
Cemile Elif Özçelik, Nazlıcan Tunç, Senem Şen, Urartu Özgür Şafak Şeker   +3 more
wiley   +1 more source

Chemical engineering as an essential element of industrial biotechnology in Mexico: New aims in research and university education

The Canadian Journal of Chemical Engineering, EarlyView.
Abstract On the centennial of higher education in Chemical Engineering in Mexico, it is pertinent to revisit the key stages that have contributed to its consolidation as a vital discipline for the nation's scientific and technological advancement. Although the initial mission of chemical engineering education was primarily oriented toward the training ...
Agustín López Munguía, Octavio T. Ramírez, Rafael Vazquez‐Duhalt, Eduardo Bárzana   +3 more
wiley   +1 more source

Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis

Clinical Pharmacology &Therapeutics, EarlyView.
In patients with systemic lupus erythematosus (SLE), increased type I interferon signaling is associated with increased disease activity across organs, including in the kidney, which can cause lupus nephritis (LN). Anifrolumab, which abrogates type I interferon signaling, is an approved treatment for moderate to severe SLE.
Joachim Almquist, Yen Lin Chia, Raj Tummala, Lynn Bertagnolli, David Jayne, Weifeng Tang, Catharina Lindholm   +6 more
wiley   +1 more source

Digital Transformation of Medicines Regulation in Africa—Perspectives from a Stakeholder Convening

Clinical Pharmacology &Therapeutics, EarlyView.
Regulatory authorities worldwide are developing strategies to integrate artificial intelligence (AI) into the lifecycle of health products, technologies, and medicines. While regulators share goals of improving efficiency, strengthening decision‐making, and protecting public health, their approaches differ according to institutional structures ...
Christelna Reyneke, Boitumelo Semete‐Makokotlela, Varnika Singh, Khanyisile Nkuku, Madelein Terblanche, Ezekiel T Mukanga, Nancy Ngum, Kudakwashe Dandajena, McNeil Chimus Mhango, Paulyne Wairimu, John Mwangi, Dominique Lagrave, Goonaseelan (Colin) Pillai   +12 more
wiley   +1 more source

Fractionation of the Caspian sand goby epidermal exudates using membrane ultrafiltration and reversed-phase chromatography: an investigation on bioactivities

Scientific Reports
Bioactive peptide-based drugs have gained exceeding attention as promising treatments for infectious and oxidative-stress-related diseases, are exacerbated by the advent and spread of various multidrug-resistant bacteria and industrial lifestyles.
Mohammad Akhavan-Bahabadi, Hamed Paknejad, Aliakbar Hedayati, Mehran Habibi-Rezaei   +3 more
doaj   +1 more source

Induction of cytochrome P450 2C9 and P‐glycoprotein activity by antiseizure medications: A systematic review and network meta‐analysis

Epileptic Disorders, EarlyView.
Abstract Objectives Antiseizure medications (ASMs) can induce the activity of drug‐metabolizing enzymes and drug transporters, including cytochrome P450 (CYP)2C9 and P‐glycoprotein (P‐gp). Our objective was to comparatively assess the effects of ASMs on exposure to clinical CYP2C9 and P‐gp substrates.
Hagar Cohen, Nahawand Bahash, Tomer Ben‐Shushan, Ilan Matok, Sara Eyal   +4 more
wiley   +1 more source

Evolution of the European Medicines Agency clinical guidelines for epilepsy drug development between 2010 and 2025: A comparative analysis by the ILAE Task Force on Regulatory Affairs

Epilepsia, EarlyView.
Abstract Objective The latest European Medicines Agency (EMA) guideline on the clinical investigation of medicines to treat epileptic disorders was adopted by the EMA Committee for Medicinal Products for Human Use in 2025. We compared this guideline with the previous version (2010), highlighting areas where significant revisions were introduced ...
Stéphane Auvin, Alexis Arzimanoglou, Jacqueline French, Kelly G. Knupp, Lieven Lagae, Eugen Trinka, Dennis Dlugos, Emilio Perucca   +7 more
wiley   +1 more source

Patterns of seizure frequency reduction in clinical trial participants with lower baseline seizure frequency

Epilepsia, EarlyView.
Abstract Objective Inclusion and exclusion criteria of clinical trials for seizures aim to select representative participants with a high enough seizure frequency to evaluate the efficacy of treatment in a relatively short double‐blind period. To inform the selection of seizure frequency‐based inclusion criteria, we evaluated the association between ...
Wesley T. Kerr, Advith S. Reddy, Neo Kok, Katherine N. McFarlane, Lavanya Biju, Jacqueline A. French   +5 more
wiley   +1 more source

Listening across frequencies: Capturing seizures of all patients to advance antiseizure medication development

Epilepsia, EarlyView.
Abstract Seizure frequency has been the primary endpoint in epilepsy trials, with enrollment usually requiring ≥4 seizures per month. This threshold is more and more misaligned with clinical reality, as the availability of more treatment options has reduced baseline seizure burden, with a risk of excluding a proportion of patients from trials. Although
Stéphane Auvin, Jacqueline French
wiley   +1 more source